(Q44743703)

5 December 2017

0 references

The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis (English)

1 reference

5 December 2017

1 reference

Karl Mann

1

1 reference

PubMed ID

14745302

5 December 2017

Philippe Lehert

series ordinal

2

1 reference

PubMed ID

14745302

5 December 2017

Marsha Y Morgan

series ordinal

3

1 reference

5 December 2017

1 January 2004

1 reference

Alcoholism: Clinical and Experimental Research

5 December 2017

1 reference

5 December 2017

28

1 reference

5 December 2017

1

1 reference

5 December 2017

51-63

1 reference

An open study with acamprosate in Belgium and Luxemburg: results on sociodemographics, supportive treatment and outcome

5 December 2017

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000108656.81563.05

A comparison of statistical methods for meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000108656.81563.05

Lifetime and 6-month prevalence of abuse and dependence of alcohol in the Munich follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000108656.81563.05

A method for assessing the quality of a randomized control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000108656.81563.05

Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000108656.81563.05

United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000108656.81563.05

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000108656.81563.05

Cognitive behavioural therapy combined with the relapse-prevention medication acamprosate: are short-term treatment outcomes for alcohol dependence improved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000108656.81563.05

Pharmacological treatment of alcohol dependence: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000108656.81563.05

Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000108656.81563.05

Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000108656.81563.05

Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000108656.81563.05

Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000108656.81563.05

The quality of alcohol treatment research: an examination of influential controlled trials and development of a quality rating system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000108656.81563.05

Methodological characteristics and quality of alcohol treatment outcome studies, 1970-98: an expanded evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000108656.81563.05

The European NEAT program: an integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol-dependent patients with a statistical modeling of therapy success prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000108656.81563.05

Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000108656.81563.05

The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000108656.81563.05

Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000108656.81563.05

Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000108656.81563.05

Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results from a non-blind, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000108656.81563.05

Drug therapy for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000108656.81563.05

10.1097/01.ALC.0000108656.81563.05

21 January 2018

Identifiers

DOI

1 reference

5 December 2017

1 reference

PubMed ID

14745302